Pfizer (PFE) has received approval from the U.S. Food and Drug Administration (FDA) for its Pneumococcal 20-valent Conjugate vaccine, PREVNAR 20, for preventing invasive pneumococcal disease and pneumonia in adults aged 18 and above. Following this approval, the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will be meeting in October to evaluate and update recommendations for the safe and appropriate use of the vaccine in adults. Kathrin U. Jansen